Biocortex
In-silico bridge trials mapping how microbiome differences change drug effects across populations, for pharma development teams
Highlights
- New on EvolcAdded 2026-11-11
About Biocortex
BioCorteX runs in-silico bridge trials that map how the bacteria in and on the body interact with a drug and differ between populations. The results show for whom an asset works and why. The work is run on NeoCorteX, the company's platform for bridge trials.
The stated customers are pharmaceutical science, regulatory and commercial teams that want to move an asset from one population to another. Clients bring their assets to the company for analysis.
BioCorteX was founded in 2021 and is registered in London, where its headquarters are. The website lists offices in London, New York and Adelaide. The company describes itself as venture capital backed.
Product: NeoCorteX, a platform behind in-silico bridge trials that show how microbiome differences affect a drug's effect across populations.
Jobs at Biocortex
More biotech & pharma companies
Biods Consulting
Computational genomics consulting for pharma, biotech and research teams working with human genomic dataNew on EvolcBioflares
Far-red and near-infrared bioluminescent imaging reagents for in-vivo research in living animalsNew on EvolcBiointeractions
Develops biocompatible coatings and materials for medical device manufacturers and implant developersNew on EvolcBioleap
Mechanistic modeling for biopharma teams making drug discovery and clinical development decisionsYoung companyNew on EvolcBiomodal
Multiomic sequencing kits that read genetic and epigenetic variants from the same DNA sample for life-science researchersBionevix
Preclinical antibody-drug conjugates targeting activated endothelium in IPF and pulmonary hypertensionNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- FastlyHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-served-by
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.